T1	intervention 29 33	Talc
T2	intervention 41 53	Iodopovidone
T3	condition 76 92	Seroma Formation
T4	eligibility 560 626	Patients with breast cancer undergoing modified radical mastectomy
T5	control 680 687	control
T6	outcome-Measure 756 785	frequency of seroma formation
T7	outcome-Measure 815 834	wound complications
T8	outcome-Measure 899 912	analgesic use
T9	outcome-Measure 914 932	postoperative pain
T10	outcome-Measure 934 953	total drain outputs
T11	outcome-Measure 959 976	drainage duration
T12	No-of-participants 985 987	86
T13	No-of-participants 1022 1024	80
T14	outcome 1126 1142	adverse outcomes
T15	outcome 1092 1104	discontinued
T16	outcome 1276 1301	prevents seroma formation
T17	intervention-value 1303 1308	19.4%
T18	control-value 1328 1333	23.3%
T20	outcome 1466 1485	less volume drained
T19	outcome 1425 1442	fewer aspirations
